# Rules of Department of Social Services
## Division 70—MO HealthNet Division
### Chapter 20—Pharmacy Program

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 CSR 70-20.010 Participating Drug Vendors (Rescinded September 30, 2018)</td>
<td>3</td>
</tr>
<tr>
<td>13 CSR 70-20.030 Drugs Covered by Medicaid</td>
<td>3</td>
</tr>
<tr>
<td>13 CSR 70-20.031 List of Excludable Drugs for Which Prior Authorization Is Required</td>
<td>4</td>
</tr>
<tr>
<td>13 CSR 70-20.032 List of Excludable Drugs Excluded From Coverage Under the MO HealthNet Pharmacy Program (Rescinded January 30, 2019)</td>
<td>4</td>
</tr>
<tr>
<td>13 CSR 70-20.033 Medicaid Program Coverage of Investigational Drugs Used in the Treatment of Acquired Immunodeficiency Syndrome (AIDS) (Rescinded September 30, 2018)</td>
<td>4</td>
</tr>
<tr>
<td>13 CSR 70-20.034 List of Non-Excludable Drugs for Which Prior Authorization Is Required</td>
<td>4</td>
</tr>
<tr>
<td>13 CSR 70-20.040 Five Prescription Limit Per Month Per Recipient (Rescinded January 30, 2019)</td>
<td>5</td>
</tr>
<tr>
<td>13 CSR 70-20.045 Thirty-One Day Supply Maximum Restriction on Pharmacy Services Reimbursed by the MO HealthNet Division</td>
<td>5</td>
</tr>
<tr>
<td>13 CSR 70-20.050 Return of Drugs</td>
<td>5</td>
</tr>
<tr>
<td>13 CSR 70-20.060 Professional Dispensing Fee</td>
<td>6</td>
</tr>
<tr>
<td>13 CSR 70-20.070 Drug Reimbursement Methodology</td>
<td>6</td>
</tr>
<tr>
<td>13 CSR 70-20.071 Multiple Source Drugs for Which There Exists a Federal Upper Limit on Reimbursement (Rescinded September 30, 2018)</td>
<td>7</td>
</tr>
<tr>
<td>13 CSR 70-20.080 Labeling of Medicaid Prescriptions (Rescinded December 9, 1993)</td>
<td>7</td>
</tr>
<tr>
<td>13 CSR 70-20.100 Missouri Nonsteroidal Anti-Inflammatory Drug List (Rescinded September 30, 1991)</td>
<td>7</td>
</tr>
<tr>
<td>13 CSR 70-20.110 Medicaid Program Coverage of Approved Drugs for Treatment of Acquired Immunodeficiency Syndrome (AIDS) (Rescinded September 30, 1991)</td>
<td>7</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>13 CSR 70-20.120</td>
<td>Medicaid Program Coverage of Anti-Ulcer Preparations (Rescinded June 29, 1989)</td>
</tr>
<tr>
<td>13 CSR 70-20.200</td>
<td>Drug Prior Authorization Process</td>
</tr>
<tr>
<td>13 CSR 70-20.250</td>
<td>Prior Authorization of New Drug Entities or New Drug Dosage Form</td>
</tr>
<tr>
<td>13 CSR 70-20.300</td>
<td>Retrospective Drug Use Review Process</td>
</tr>
<tr>
<td>13 CSR 70-20.310</td>
<td>Prospective Drug Use Review Process and Patient Counseling</td>
</tr>
<tr>
<td>13 CSR 70-20.320</td>
<td>Pharmacy Reimbursement Allowance</td>
</tr>
<tr>
<td>13 CSR 70-20.330</td>
<td>Medication Therapy Management (MTM) Program</td>
</tr>
</tbody>
</table>
Title 13—DEPARTMENT OF SOCIAL SERVICES
Division 70—MO HealthNet Division
Chapter 20—Pharmacy Program

13 CSR 70-20.010 Participating Drug Vendors
(Rescinded September 30, 2018)


13 CSR 70-20.030 Drugs Covered by Medicaid

PURPOSE: This rule implements recent changes in drug coverage as mandated by federal Health Care Financing Administration.

(1) Limiting Definition—As defined in the Social Security Act, section 1927(k)(3), the term covered outpatient drug does not include any drug, biological product, or insulin provided as part of, or as incident to and in the same setting as any of the following (and for which payment may be made under this title as part of payment for the following and not as direct reimbursement for the drug):

(A) Inpatient hospital services.

(B) Hospice services.

(C) Dental services, except that drugs for which the state plan authorized direct reimbursement to the dispensing dentist are covered outpatient drugs.

(D) Physicians’ services.

(E) Outpatient hospital services.

(F) Nursing facility services and services provided by an intermediate care facility for the mentally retarded.

(G) Other laboratory and x-ray services.

(H) Renal dialysis.

“Such term also does not include any such drug or product for which a National Drug Code number is not required by the Food and Drug Administration or a drug or biological used for a medical indication which is not a medically accepted indication.”

(2) Participating Manufacturers—The Missouri Division of Medical Services identifies those manufacturers whose products are reimbursable along with effective dates of coverage, based on date of service, corresponding to effective dates of their participation under the national rebate contract. All products marketed by participating manufacturers are reimbursable, with the following exceptions: those products identified as Drug Efficacy Study Implementation (DESI) drugs by the federal Food and Drug Administration (FDA); products considered by the federal FDA to be similar, identical or related to a DESI product; products identified in 13 CSR 70-20.031 and 13 CSR 70-20.032; and products not meeting the definition of drug in sections 505, 506 and 507 of the federal Food, Drug and Cosmetic Act.

(3) According to the federal Social Security Act, section 1927(a)(1) in order for federal financial participation to be available for covered outpatient drugs of a manufacturer, the manufacturer must have entered into and have in effect a rebate agreement with the secretary of the federal Department of Health and Human Services. States are periodically notified by the federal Health Care Financing Administration of manufacturers that have entered into as well as terminated rebate agreements with the secretary of the federal Department of Health and Human Services. The Missouri Medicaid Pharmacy Manual and updating bulletins shall provide the detailed listing of manufacturers that have in effect a rebate agreement with the federal Department of Health and Human Services.

13 CSR 70-20.031 List of Excludable Drugs for Which Prior Authorization Is Required

PURPOSE: This rule establishes a listing of excludable drugs and categories of drugs for which prior authorization is required in order for them to be reimbursable under the MO HealthNet Pharmacy Program.

PUBLISHER’S NOTE: The secretary of state has determined that the publication of the entire text of the material which is incorporated by reference as a portion of this rule would be unduly cumbersome or expensive. This material as incorporated by reference in this rule shall be maintained by the agency at its headquarters and shall be made available to the public for inspection and copying at no more than the actual cost of reproduction. This note applies only to the reference material. The entire text of the rule is printed here.

(1) Permissible Exclusions—As specified in the Social Security Act, Section 1927(d)(1)(B), states may exclude or otherwise restrict coverage of certain covered outpatient drugs. Section 1927(d)(2) of the Social Security Act provides a listing of the categories of drugs that are permissible for exclusion. Drugs included on this list may be excluded from coverage entirely or restricted by diagnosis as determined by the state.

(2) As specified in Section 1927(d)(1) of the Social Security Act, states may subject to prior authorization any covered outpatient drug. Any such prior authorization program shall comply with the requirements of Section 1927(d)(5) of the Social Security Act.

(3) List of drugs or categories of excludable drugs which are restricted to require prior authorization for certain specified indications shall be made available through the Department of Social Services, MO HealthNet Division website at dss.mo.gov/mhd, provider bulletins, and updates to the provider manual which are incorporated by reference and made a part of this rule as published by the Department of Social Services, MO HealthNet Division, 615 Howerton Court, Jefferson City, MO 65109, at its website, October 15, 2013. This rule does not incorporate any subsequent amendments or additions. The division reserves the right to affect changes in the list of excludable drugs for which prior authorization is required by amending this rule.


13 CSR 70-20.032 List of Excludable Drugs Excluded From Coverage Under the MO HealthNet Pharmacy Program

(Rescinded January 30, 2019)


13 CSR 70-20.033 Medicaid Program Coverage of Investigational Drugs Used in the Treatment of Acquired Immunodeficiency Syndrome (AIDS)

(Rescinded September 30, 2018)


13 CSR 70-20.034 List of Non-Excludable Drugs for Which Prior Authorization Is Required

PURPOSE: This rule establishes a listing of non-excludable drugs and categories of drugs for which prior authorization is required in order for them to be reimbursable under the MO HealthNet Pharmacy Program.

PUBLISHER’S NOTE: The secretary of state has determined that the publication of the entire text of the material which is incorporated by reference as a portion of this rule would be unduly cumbersome or expensive. This material as incorporated by reference in this rule shall be maintained by the agency at its headquarters and shall be made available to the public for inspection and copying at no more than the actual cost of reproduction. This note applies only to the reference material. The entire text of the rule is printed here.

(1) As specified in section 1927(d)(1) of the Social Security Act, states may subject to prior authorization any covered outpatient drug. Any such prior authorization program shall comply with the requirements of section 1927(d)(5) of the Social Security Act.

(2) List of drugs or categories of drugs which are restricted to require prior authorization for certain specified indications shall be made available through the Department of Social Services, MO HealthNet Division website at www.dss.mo.gov/mhd, provider bulletins,
and updates to the provider manual which are incorporated by reference and made a part of this rule as published by the Department of Social Services, MO HealthNet Division, 615 Howerton Court, Jefferson City, MO 65109, at its website, September 15, 2009. This rule does not incorporate any subsequent amendments or additions. The division reserves the right to affect changes in prior authorization of non-excludable drugs by amending this rule.


13 CSR 70-20.040 Five Prescription Limit Per Month Per Recipient  
(Rescinded January 30, 2019)


13 CSR 70-20.045 Thirty-One Day Supply Maximum Restriction on Pharmacy Services Reimbursed by the MO HealthNet Division

PURPOSE: This rule establishes a thirty-one (31) day supply maximum restriction per dispensing on pharmacy services reimbursed by the MO HealthNet Division on behalf of patients eligible for any of the fee-for-service programs.

PUBLISHER’S NOTE: The secretary of state has determined that the publication of the entire text of the material which is incorporated by reference as a portion of this rule would be unduly cumbersome or expensive. This material as incorporated by reference in this rule shall be maintained by the agency at its headquarters and shall be made available to the public for inspection and copying at no more than the actual cost of reproduction. This note applies only to the reference material. The entire text of the rule is printed here.

(1) The maximum days supply of medication which may be provided per dispensing on behalf of a patient eligible for any of the fee-for-service programs is thirty-one (31) day supply, except for those drugs and/or categories of medications which are exempt from the thirty-one (31) day supply limitation by this rule.

(2) Drugs and/or categories of medications which are exempt from the thirty-one (31) day supply limitation and therefore may be dispensed in quantities exceeding a thirty-one (31) day supply are made available in the MO HealthNet Pharmacy Manual, section 13.6.D(1), located through the Department of Social Services, MO HealthNet Division website at manuals.momed.com/manuals, which is incorporated by reference and made part of this rule as published by the Department of Social Services, MO HealthNet Division, 615 Howerton Court, Jefferson City, MO 65109, at its website, April 18, 2018. This rule does not incorporate any subsequent amendments or additions. The division reserves the right to affect changes in the list of drugs and/or categories of medications which are exempt from the thirty-one (31) day supply limitation by amending this rule.

(3) All spend down recipients are exempt from the MO HealthNet thirty-one (31) day supply maximum restriction on pharmacy services.

(4) Exemptions from the thirty-one (31) day supply limitation may be given with prior authorization by the MO HealthNet Division to prevent a higher level of care.


13 CSR 70-20.050 Return of Drugs

PURPOSE: This rule establishes that when a pharmacy dispenses drugs in a controlled-dose delivery system, the pharmacy must give the MO HealthNet Division credit for any unused portion of the drug that is reusable in accordance with applicable federal or state law.

(1) Definitions.

(A) Controlled-dose delivery system. A controlled-dose delivery system is defined as a system of dispensing of medications on behalf of a resident in a long-term care facility in manufacturer’s unit dose packaging or pharmacist packager’s unit dose, unit-of-use, or strip packaging with each tablet or capsule individually wrapped, or in blister cards, all of which must be dispensed according to applicable state and federal laws or regulations.

(2) The return and reuse of drugs must follow guidelines set by the State Board of Pharmacy in 20 CSR 2220-3.040, as amended.

(3) When a pharmacy dispenses drugs in a
controlled-dose delivery system the pharmacy must give the MO HealthNet Division credit for all reusable items (any unused portion) not taken by the MO HealthNet participant. In instances in which charges have been submitted prior to the return of an item the pharmacy shall file an adjustment to notify the MO HealthNet Division of the need to process a credit. The dispensing pharmacy that receives the returned drugs must provide a credit to the MO HealthNet Division for the amount reimbursed for drug costs from which the prescription was billed, prorated to the quantity of the drug returned. The credited amount should not include dispensing fees.


13 CSR 70-20.060 Professional Dispensing Fee

PURPOSE: The MO HealthNet Division establishes the amount of the fee reimbursable for the professional dispensing of each MO HealthNet covered prescription by a pharmacy provider, raises the current dispensing fee from three dollars ($3) to four dollars eighty-four cents ($4.84) and establishes a long-term care prescription fee add-on of fifteen cents (15¢).

PUBLISHER’S NOTE: The secretary of state has determined that the publication of the entire text of the material which is incorporated by reference as a portion of this rule would be unduly cumbersome or expensive. Therefore, the material which is so incorporated is on file with the agency who filed this rule, and with the Office of the Secretary of State. Any interested person may view this material at either agency’s headquarters or the same will be made available at the Office of the Secretary of State at a cost not to exceed actual cost of copy reproduction. The entire text of the rule is printed here. This note refers only to the incorporated by reference material.

1. Dispense medication in a drug distribution system(s) which meets minimum standards of container packaging (at least class B as defined in United States Pharmacopeia XXII);
2. Certify to the MO HealthNet Division, on a form, and in the manner prescribed by the division, that they—
   (A) Dispense medication in a drug distribution system(s) which meets minimum standards of container packaging (at least class B as defined in United States Pharmacopeia XXII);
   (B) Certify to the MO HealthNet Division, on a form, and in the manner prescribed by the division, that they—
   (C) Indicate, as prescribed by the MO HealthNet Division, on each claim that the prescription was provided in packaging qualifying for the dispensing fee add-on to a participant in a long-term care facility.


13 CSR 70-20.070 Drug Reimbursement Methodology

PURPOSE: This rule establishes the basis and the method for pricing all drug claims in Missouri under the Title XIX Medicaid program. The purchase of a computer-generated tape, with weekly updates, will make it possible to utilize the computer for review purposes, which greatly increases the speed with which claims can be paid.

1. The MO HealthNet Division will obtain, by contract with a reputable medical publishing company, a weekly computer-generated tape which will provide the information needed to price all fee-for-service Medicaid drug claims. The tape will contain National Drug Code (NDC), drug name, drug strength, dosage form, package size, the prices set by direct-selling manufacturers (direct prices), Wholesaler Acquisition Cost (WAC), federal Health and Human Services upper limits for specified multiple source drugs (FUL), and National Average Drug Acquisition Cost (NADAC). A multiple source drug is defined as a drug marketed or sold by two (2) or more manufacturers or labelers, or a drug marketed or sold by the same manufacturer or labeler under two (2) or more different proprietary names or both under a proprietary name and without that name.

2. The MO HealthNet Division will add the Missouri Maximum Allowable Cost (MMAC) limits, for multiple source drugs as defined, to the data shown on the tape described in section (1) of this rule.

3. Reimbursement for covered drugs dispensed between April 1, 2017, and December 15, 2018, will be determined by applying the following hierarchy method:
   (A) Federal Upper Limit (FUL) price; if there is no FUL;
   (B) Missouri Maximum Allowed Cost (MAC); if no FUL or MAC;
   (C) Wholesale Acquisition Cost (WAC) minus three and one-tenth percent (3.1%); or
   (D) The usual and customary (U&C) charge submitted by the provider if it is lower than the chosen price (FUL, MAC, or WAC).

4. Effective December 16, 2018, reimbursement for covered drugs will be determined by applying the following hierarchy method:
   (A) National Average Drug Acquisition Cost (NADAC); if there is no NADAC;
   (B) Missouri Maximum Allowed Cost (MAC); if no NADAC or MAC;
   (C) Wholesale Acquisition Cost (WAC); or
   (D) The usual and customary (U&C) charge submitted by the provider if it is lower than the chosen price (NADAC, MAC, or WAC).

5. Between April 1, 2017, and December 15, 2018, reimbursement for covered drugs for 340B providers as defined by the Public Health Service Veterans Health Care Act of 1992 who carve-in for Medicaid will be determined by applying the following method:
   (A) Wholesale Acquisition Cost (WAC) minus forty-nine percent (49%); or
   (B) The usual and customary (U&C) charge submitted by the provider if it is lower.

6. Effective December 16, 2018, reimbursement for covered drugs for 340B providers as defined by the Public Health Service Veterans...
Health Care Act of 1992 who carve-in for Medicaid will be determined by applying the following method:

(A) Wholesale Acquisition Cost (WAC) minus twenty-five percent (25%); or

(B) The usual and customary (U&C) charge submitted by the provider if it is lower.

(7) The professional dispensing fee will be calculated according to 13 CSR 70-20.060.


13 CSR 70-20.071 Multiple Source Drugs for Which There Exists a Federal Upper Limit on Reimbursement

(Rescinded September 30, 2018)


13 CSR 70-20.080 Labeling of Medicaid Prescriptions

(Rescinded December 9, 1993)


13 CSR 70-20.100 Missouri Nonsteroidal Anti-Inflammatory Drug List

(Rescinded September 30, 1991)


13 CSR 70-20.110 Medicaid Program Coverage of Approved Drugs for Treatment of Acquired Immunodeficiency Syndrome (AIDS)

(Rescinded September 30, 1991)


13 CSR 70-20.120 Medicaid Program Coverage of Anti-Ulcer Preparations

(Rescinded June 29, 1989)


13 CSR 70-20.200 Drug Prior Authorization Process

PURPOSE: This rule establishes the division process by which drugs may be restricted under Section 4401 of P.L. 101-508 (Omnibus Budget Reconciliation Act of 1990) and are determined to be appropriate for inclusion as a regular benefit of the MO HealthNet program or through prior authorization.

(1) The following definitions shall be used in the interpretation and enforcement of this rule:

(A) “Clinical editing” shall be defined as a process which screens the use of specific medications on the basis of clinical appropriateness by requiring evidence of appropriate indications for use, and to achieve a cost savings, may require the initial use of less expensive agents.

(B) “Fiscal editing” shall be defined as a process that screens the use of specific medications to reimburse based on the least expensive dosage forms in order to achieve a cost savings.

(C) “Open access” shall be defined as the availability of a product without being subject to prior authorization, clinical edits or step therapy but shall not preclude fiscal and utilization edits.

(D) “Preferred Drug List” shall be defined as a list of medications within a functional therapeutic class that are available via open access on the basis of supplemental rebate status and consideration of available evidence-based clinical review findings.

(E) “Step therapy” shall be defined as a process that specifies the sequence in which different prescription drugs are to be reimbursed.

(F) “Utilization edits” are defined as prospective screening edits used to review the appropriate use of medication and may be advisory or preemptory.
(2) This rule establishes a MO HealthNet Drug Prior Authorization Committee in the Department of Social Services, MO HealthNet Division. The committee shall be composed of three (3) practicing physicians licensed pursuant to Chapter 334, RSMo; three (3) practicing pharmacists licensed pursuant to Chapter 338, RSMo, one (1) of whom shall hold a doctoral degree in pharmacy (Pharm. D.); and one (1) registered professional nurse, as defined in Chapter 335, RSMo, practicing in a long-term care setting. All members shall be appointed by the director of the Department of Social Services. The members shall serve for a term of four (4) years. Members of the committee shall receive no compensation for their services, but shall be reimbursed for their actual and necessary expenses incurred, as approved by the MO HealthNet Division out of appropriations made for that purpose. The MO HealthNet Drug Prior Authorization Committee shall meet quarterly. The proposed dates for the meetings shall be announced for one (1) calendar year at the last meeting of the previous calendar year. If a meeting date is changed the new date must be posted at www.dss.mo.gov/mhd for at least thirty (30) days prior to the originally scheduled meeting.

(3) All persons eligible for medical assistance benefits shall have access to all pharmaceutical products for which there is federal financial participation except those drugs that may be restricted under Section 4401 of P.L. 101-508 (Omnibus Budget Reconciliation Act of 1990). The MO HealthNet Drug Prior Authorization Committee shall review those drugs that may be restricted and recommend those appropriate for inclusion as a regular benefit of the MO HealthNet program or through prior authorization.

(4) The department or the division may require prior authorization of pharmaceutical products. Any such restriction shall be based on specific data. The committee shall develop this medical and clinical criteria based on predetermined standards consistent with the following:

(A) The American Hospital Formulary Service Drug Information;

(B) The United States Pharmacopoeia Drug Information; and

(C) Peer-reviewed medical literature.

(5) If the division finds that the data enumerated in section (4) of this rule has been documented, the MO HealthNet Drug Prior Authorization Committee shall hold a public hearing prior to making recommendations to the department and prior to any final decision by the division to require prior authorization for that pharmaceutical product, class, or category.

(6) The tentative meeting agenda of the MO HealthNet Drug Prior Authorization Committee with the classes to be discussed shall be posted on the MO HealthNet Division website (www.dss.mo.gov/mhd) approximately fourteen (14) days prior but no less than seven (7) days prior to the meeting.

(A) The specific therapeutic class or classes to be considered at the next regularly scheduled MO HealthNet Drug Prior Authorization Committee meeting shall be placed on the current agenda or posted on the website approximately thirty (30) days prior to the scheduled meeting.

(B) Any interested party shall be granted the opportunity for clinically relevant public comment for up to fifteen (15) minutes in the aggregate per medication under review by the committee. The responsibility of scheduling the presentation shall rest with the manufacturer of the drug product.

(C) Following the consideration of all presented information, the committee shall make their final recommendation to the MO HealthNet Division by a majority vote of the members of the committee present thereto in a recorded roll call vote.

(D) The specific therapeutic class or classes recommended for restriction by means of step therapy, clinical edit, fiscal edit, or preferred drug list shall be available on the division website at www.dss.mo.gov/mhd approximately fifteen (15) calendar days after the meeting.

(7) The recommendations from the MO HealthNet Drug Prior Authorization Committee shall be referred to the Drug Utilization Review (DUR) Board for placement upon the agenda of the next regularly scheduled meeting. The DUR board may accept or alter the recommendations from the MO HealthNet Drug Prior Authorization Committee in arriving at their recommendations for the MO HealthNet Division. If provided to the division fourteen (14) days in advance of the DUR board meeting, clinically relevant written material shall be presented before the recommendation is considered by the DUR board. The DUR board, at their sole discretion, may entertain clinically relevant public comment up to fifteen (15) minutes in aggregate per medication. The responsibility of scheduling the presentation shall rest with the manufacturer of the drug product. Any changes recommended by the DUR board shall be made available via the approved minutes of the DUR board meeting in a timely fashion, at least thirty (30) days prior to the implementation of the recommendations.

(8) After all recommendations have been reviewed and accepted, the MO HealthNet Division staff shall coordinate the implementation of the recommendations. All pertinent information relating to edit schedule and edit criteria shall be made available to the public by reasonable means, including, but not limited to, posting on the division website in a timely fashion following the DUR board meeting. Changes to the MO HealthNet pharmacy benefit will be posted on a timely basis on the division website. In addition, information on covered medications shall be made available to the public for use with a personal digital assistant device. As determined by the division, patients stabilized on certain restricted medications shall be allowed to access such medication through the MO HealthNet program for as long as the MO HealthNet program determines that it is fiscally prudent and clinically supported.

(9) On an annual basis, the MO HealthNet Drug Prior Authorization Committee shall review all criteria in place, including prior authorization, step therapy, clinical edits, fiscal edits, and the preferred drug list. Annual reviews will be staggered and scheduled to occur at the scheduled meeting closest to completion of a full calendar year after approval of the criteria. If additional clinical or fiscal information is available since the original consideration, interested parties shall have the opportunity to address the committee and request reconsideration of prior authorization, step therapy, clinical edits, fiscal edits, and preferred drug list criteria. All requests shall be scheduled with the division fourteen (14) days in advance of the meeting. All such presentations shall be clinically relevant and limited to a maximum of fifteen (15) minutes. The responsibility of scheduling the presentation shall rest with the manufacturer of the drug product.

(10) The division shall not otherwise restrict the prescribing and dispensing of covered outpatient prescription drugs (other than Drug Efficacy Study Implementation (DESI) drugs as designated by federal law) pursuant to this rule without consulting the Drug Prior Authorization Committee. The division may limit the number of prescriptions allowed for each medical assistance participant.

(11) As used in the rule, DESI drugs are
drugs described in section 107(c)(3) of the Drug Amendments of 1962 and identical, similar or related drugs (within the meaning of section 310.6(b)(1) of Title 21 of the Code of Federal Regulations).

(12) When implementing the provisions of section (4), Missouri-specific data shall include the consideration of use and cost data, pharmacoeconomic information and prudent utilization of state funds, and shall include medical and clinical criteria.


**13 CSR 70-20.250 Prior Authorization of New Drug Entities or New Drug Dosage Form**

**PURPOSE:** This rule outlines the process by which new drugs or new drug dosage forms of existing drugs may be subject to prior authorization prior to payment by Missouri’s medical assistance program.

(1) New drug entities, and new drug product dosage forms of existing drug entities, that have been approved by the Food and Drug Administration and are available on the market, shall comply with prior authorization requirements imposed by the division, in compliance with federal law.

(2) Prior authorization restrictions shall continue on new drug entities and new drug product dosage forms of existing drugs until reviewed by the division and the division eliminates the restriction or makes a final determination to require restriction. The division shall consider known cost and use data, medical and clinical criteria, and prudent utilization of state funds in the review. Interested parties may present clinical data to the division.

(3) The review referenced in section (2) shall occur within thirty (30) business days after the division receives notice through pricing updates of the availability of the drug entity on the market. Upon completion of the review, the division shall make the drug available for use by all MO HealthNet participants or refer the new drug or new drug dosage form to the MO HealthNet Drug Prior Authorization Committee (MDPAC) with a recommendation for continued prior authorization. Staff recommendations regarding continued prior authorization of a new drug or new drug dosage form shall be made in writing to the MDPAC. A copy shall be available to the public prior to the MDPAC meeting in which the continued prior authorization is to be discussed.

(4) The MDPAC shall consider any recommendations related to continued prior authorization of a new drug or new drug dosage form at the next scheduled MDPAC meeting. The division and the MDPAC may actively seek comments about the proposed restrictions. The MDPAC shall include a minimum of fifteen (15) minutes for any interested parties who have notified the division in advance of the scheduled meeting to comment about such proposed restrictions.

(5) If the MDPAC finds that use and cost data, pharmacoeconomic information, along with medical and clinical implications of restriction, are documented and restriction is warranted, the MDPAC shall hold a public hearing regarding the continued restriction and make a recommendation to the division. Such recommendation shall be provided to the division, in writing, prior to the division making a final determination. The division shall provide notice of the final determination through the Department of Social Services, MO HealthNet Division website at dss.state.mo.gov/mld, provider bulletins, and updates to the provider manual.

(6) If, after the hearing referenced in section (5) above, prior authorization of the new drug or new drug dosage form is required, the prior authorization requirement shall be reviewed at least once every twelve (12) months by the MDPAC.


**13 CSR 70-20.300 Retrospective Drug Use Review Process**

**PURPOSE:** This rule establishes the division process by which the Drug Use Review Board will be established as required by Section 4401 of P.L. 101-508 (Omnibus Budget Reconciliation Act of 1990) and by section 208.175, RSMo.

(1) Drug Use Review (DUR) Board. This rule establishes a MO HealthNet DUR board in the Department of Social Services, MO HealthNet Division. The board shall be composed as specified in section 208.175, RSMo.

(2) Members of the DUR board must have the following minimum qualifications:

A. Must be licensed by Missouri, with that license in active status and in good standing; and

B. Must have recognized knowledge and expertise in one (1) or more of the following:

1. The clinically appropriate prescribing of covered outpatient drugs;

2. The clinically appropriate dispensing and monitoring of covered outpatient drugs;

3. Drug use review, evaluation, and intervention; or

4. Medical quality assurance.

(3) A chairperson shall be elected by the board members.

(4) The board shall meet at least once every ninety (90) days. A quorum of two-thirds (2/3) of the total members, including no fewer than two (2) physicians or two (2) pharmacists, is required for the board to act in its official capacity.

(5) Members shall serve four (4)-year terms, except the terms of the original members, two (2) shall be appointed for a term of two (2) years, three (3) shall be appointed for a term of three (3) years, and three (3) shall be appointed for a term of four (4) years. Members may be reappointed, provided that minimum qualifications for membership continue to be met. Nominations shall be referred for final appointment by the governor subject to advice and consent of the senate. As vacancies occur, the DUR board shall solicit and select a slate of nominees.

(6) The members of the board shall receive no compensation for their services other than reasonable expenses actually incurred in the performance of their official duties.

(7) The DUR board shall provide, either directly or through contracts between the MO HealthNet Division and accredited health care schools, state medical societies or state pharmacist associations or societies or other...
appropriate organizations, for educational outreach programs as required by P.L. 101-508, Section 4401, to educate practitioners on common drug therapy problems with the aim of improving prescribing and dispensing practices. This outreach shall include an educational newsletter to MO HealthNet providers including appropriate drug use guidelines and MO HealthNet utilization statistics.

(8) As specified by P.L. 101-508, Section 4401, the DUR board shall monitor drug use, and prescribing and dispensing practices in the MO HealthNet program. This monitoring shall include reviewing and refining therapeutic criteria modules used in both retrospective and prospective DUR, as well as overseeing retrospective DUR intervention methods used.

(9) The DUR board shall advise the Department of Social Services regarding all activities associated with the DUR process, including identifying types of intervention methods to be initiated by the review committees, ranging from letters to physicians and pharmacists, face-to-face education and educational symposiums for targeted providers. The board shall provide educational support and guidance as needed by the review committees. The review committees, in turn, shall report intervention results and make recommendations based on these results to the board.

(10) The DUR board shall review and research recommendations from the Drug Prior Authorization Committee, as established by 13 CSR 70-20.200, regarding the advisability of implementing or removing prior authorization requirements for a drug or class of drugs, and make a recommendation to the Department of Social Services.

(11) Specialized DUR Committees. Subject to appropriation, up to six (6) regional review committees may be appointed by the director of the Department of Social Services for the areas surrounding St. Louis, Kansas City, Springfield, Cape Girardeau, Kirksville and Columbia. Other specialized review committees may be formed at the discretion of the Department of Social Services. Members of the review committees shall be physicians and pharmacists appointed by the DUR board, totaling no fewer than five (5) and no more than ten (10) members per committee. A quorum of fifty-one percent (51%) of the total members must be present to conduct business. Regional committee members shall have the same minimum qualifications as required for the DUR board members. Regional committee meetings shall be held every other month. The members of each committee shall elect a chairperson, who shall serve as an ex officio member of the DUR board. Committee members shall receive no compensation other than reasonable expenses actually incurred in the performance of their official duties.

(12) The regional review committees shall conduct patient profile reviews, including opening and closing of cases at the committee meetings. Interventions shall be initiated and follow-up reviews performed by the regional committees. Patterns of inappropriate or aberrant prescribing or dispensing shall be identified and referred to the board in order for targeted education to be formulated.

(13) Agency Responsibility Regarding Confidentiality of Information. All information concerning applicants and MO HealthNet participants shall be confidential and any disclosure of this information shall be restricted to purposes directly related to the administration of the medical assistance program. Purposes directly related to administration of the medical assistance program include:

(A) Establishing eligibility;
(B) Determining the amount of medical assistance;
(C) Providing services for recipients; and
(D) Conducting or assisting an investigation, prosecution, or civil or criminal proceeding related to the administration of the program.

(14) Provider Responsibility Regarding Confidentiality of Information. All information concerning applicants and participants of medical services shall be confidential. Any disclosure of this information shall be restricted to purposes directly related to the treatment of the patient and promotion of improved quality of care. The confidential information includes:

(A) Names and addresses;
(B) Social Security number;
(C) Medical services provided;
(D) Social and economic conditions or circumstances;
(E) Medical data, including diagnosis and past history of disease or disability;
(F) Any information received for verifying income eligibility; and
(G) Any information received in connection with the identification of legally liable third-party resources.


13 CSR 70-20.310 Prospective Drug Use Review Process and Patient Counseling

PURPOSE: This rule establishes provisions for prospective drug use review and patient counseling for MO HealthNet beneficiaries, as required by Section 4401 or Public Law 101-508 (Omnibus Budget Reconciliation Act of 1990) and by section 208.176, RSMo.

(1) Prospective Drug Use Review (DUR). This rule establishes a MO HealthNet prospective drug use review process within the Department of Social Services, MO HealthNet Division, as specified in section 208.176, RSMo.

(2) Electronic Point-of-Sale Review. The MO HealthNet Division shall provide for electronic point-of-sale review of drug therapy using predetermined standards before each prescription is dispensed to the MO HealthNet participant or MO HealthNet participant’s caregiver for the current date of service. The process will provide screening for potential drug therapy problems using clinical modules which have been reviewed and approved for use by the Missouri Drug Use Review Board.

(3) Federal Prospective DUR screening requirements for MO HealthNet beneficiaries. 42 CFR part 456.705(b) requires that the state plan must provide for a point of distribution review of drug therapy using predetermined standards before each prescription is filled or delivered to the participant or the participant’s caregiver. The review, performed with or without online access to the pharmacy point of sale system, must include screening to identify potential drug therapy problems of the following types:

(A) Incorrect drug dosage, that is, the dosage lies outside the daily dosage range specified in predetermined standards as necessary to achieve therapeutic benefit. Dosage range is the strength multiplied by the quantity dispensed divided by days supply;
(B) Adverse drug-drug interaction, that is, the potential for, or occurrence of, an adverse medical effect as a result of the participant using two (2) or more drugs together;
(C) Drug-disease contraindication, that is the potential for, or occurrence of—

1. An undesirable alteration of the therapeutic effect of a given prescription because
of the presence, in the patient for whom it is
prescribed, of a disease condition; or

2. An adverse effect of the drug on the
patient’s disease condition.

(D) Therapeutic duplication, that is, the
prescribing and dispensing of two (2) or more
drugs from the same therapeutic class so that
the combined daily dose puts the participant
at risk of an adverse medical result or incurs
additional program costs without additional
therapeutic benefit;

(E) Incorrect duration of drug treatment,
that is, the number of days of prescribed ther-
apy exceeds or falls short of the recommenda-
tions contained in the predetermined stan-
dards;

(F) Drug-allergy interactions, that is, the
significant potential for, or the occurrence of,
an allergic reaction as a result of drug thera-
py; and

(G) Clinical abuse/misuse, that is, the
occurrence of situations referred to in the
definitions of abuse, gross overuse, overuti-
лизация и underutilization, as defined in 42
CFR 456.702, and incorrect dosage and
incorrect duration, as defined in subsections
(3)(A) and (E) of this rule.

(4) Screens Available for MO HealthNet
Beneficiaries. The following screens will be
provided by the pharmacy point of service
system:

(A) Drug Disease Contraindications.
1. Drug (actual) disease precaution.
2. Inferred Drug Disease precaution;

(B) Drug to Drug Interactions;
(C) Side Effects.
1. Additive toxicity side effects.
2. Medical condition/additive side
effect;
3. Side effect.
4. Drug indicated for side effect of pre-
viously prescribed drug;

(D) Dose Range Checking.
1. High dose alert.
2. Low dose alert;

(E) Minimum/Maximum Daily Dose.
1. High dose alert.
2. Low dose alert;

(F) Duplicate Therapy Checking.
1. Therapeutic duplication.
2. Ingredient duplication; and

(G) Duration of Therapy (H2).
1. Excessive duration alert.

(5) MO HealthNet Patient Counseling. As
part of the prospective DUR program, particip-
ating pharmacies shall perform patient
counseling according to the standards estab-
lished by the Board of Pharmacy under 20
CSR 2220-2.190.

(6) MO HealthNet Patient Profiles. The term,
reasonable effort means that each time a MO
HealthNet patient or caregiver presents a pre-
scription, the pharmacist or pharmacist’s
designee should request profile information
verbally or in writing. For example, if the
patient presents the prescription in person,
the request should be made verbally, and if the
prescription is received by mail, the
request should be made in writing. This does
not imply that the service should be denied
solely on the basis of the patient’s refusal to
supply this information. Pharmacies must
make a reasonable effort to obtain records
and maintain patient profiles containing, at a
minimum:

(A) The name, address, telephone number,
date of birth (or age), and gender of the patient;

(B) Individual medical history, if signifi-
cant, including disease states, known aller-
gies and drug reactions, and a comprehensive
list of medications and relevant devices; and

(C) Pharmacist’s comments relevant to the
individual’s drug therapy.

(7) Documentation of Offer to Counsel. The
pharmacist shall document for each
MO HealthNet patient’s prescription in a uni-
form fashion, whether the offer to counsel was
accepted or refused by the patient or the
patient’s agent.

(8) Agency Responsibility Regarding Con-
fidentiality of Information. All information
concerning applicants and participants of med-
ical services shall be kept confidential by the
MO HealthNet Division, and any disclosure of
this information shall be restricted to purposes
directly related to the administration of the
medical assistance program. Purposes directly
related to administration of the medical assis-
tance program include:

(A) Establishing eligibility;

(B) Determining the amount of medical
assistance;

(C) Providing services for participants; and

(D) Conducting or assisting an investiga-
tion, prosecution, or civil or criminal pro-
ceding related to the administration of the
program.

(9) Provider Responsibility Regarding Con-
fidentiality of MO HealthNet Beneficiary
Information. All information concerning
applicants and participants of medical ser-
vice shall be confidential. Any disclosure of
this information by the pharmacy provider
shall be restricted to purposes directly related
to the treatment of the patient and promotion
of improved quality of care, or conducting or
assisting an investigation, prosecution, or
civil or criminal proceeding related to the
administration of the program. The confiden-
tial information includes:

(A) Names and addresses;

(B) Social Security number;

(C) Medical services provided;

(D) Social and economic conditions or cir-
cumstances;

(E) Medical data, including diagnosis and
past history of disease or disability;

(F) Any information received for verifying
income eligibility; and

(G) Any information received in connec-
tion with the identification of legally liable
third party resources.

AUTHORITY: sections 208.153 and 208.201,

13 CSR 70-20.320 Pharmacy Reimburse-
ment Allowance

PURPOSE: This rule establishes a Pharmacy
Federal Reimbursement Allowance and the
methodologies to determine the formula for
the amount of allowance each pharmacy is
required to pay for the privilege of providing
outpatient prescription drugs.

(1) Pharmacy Reimbursement Allowance
(PRA). PRA shall be assessed as described in
this section.

(A) Definitions.
1. Department—Department of Social
Services.

2. Director—Director of Department of
Social Services.

3. Division—MO HealthNet Division.
4. Gross retail prescription receipts—
For ease of administration for the department
as well as the industry, this shall be an annual
amount. The basis of tax in any fiscal year
will be the gross prescription sales of the last
calendar year prior to the previous fiscal
year.

(B) Each pharmacy engaging in the busi-
ness of providing outpatient prescription
drugs in Missouri to the general public shall
pay a PRA.

1. The PRA owed for existing pharma-
cies shall be calculated by multiplying the
pharmacy’s total gross retail prescription
receipts by the tax rate determined by the
department. Subject to the limitations estab-
ish ed in section 338.520, RSMo, such said
tax rate shall be uniform and shall not exceed
five percent (5%).
2. The PRA shall be divided by and collected over the number of months for which the PRA is effective.

3. The initial PRA owed by a newly licensed pharmacy shall be calculated by estimating the total prescription sales and multiplying the estimate by the rate determined by the department, as described in paragraph (1)(B).

4. If a pharmacy ceases to provide outpatient prescription drugs to the general public, the pharmacy is not required to pay the PRA during the time it did not provide outpatient prescription drugs.

5. If the pharmacy reopens, it shall resume paying the PRA. It shall owe the same PRA as it did prior to closing, if the PRA has not changed per paragraph (1)(B).

(C) Each pharmacy shall submit an affidavit to the department with the following information:

1. Pharmacy name;
2. Contact;
3. Telephone number;
4. Address;
5. Federal tax ID number;
6. MO HealthNet pharmacy number (if applicable);
7. Pharmacy sales (total);
8. MO HealthNet pharmacy sales;
9. Number of paid MO HealthNet prescriptions; and
10. Gross receipts attributable to prescription drugs that are delivered directly to the patient via common carrier, by mail, or a courier service.

(D) The department shall prepare a confirmation schedule of the information provided by each pharmacy and the amount of PRA that is due from the pharmacy.

(E) Each pharmacy shall review the information prepared by the department and the amount of PRA calculated by the department to verify that the information is correct.

1. If the information supplied by the department is incorrect, the facility, within thirty (30) calendar days of receiving the confirmation schedule, must notify the division and explain the correction.

2. If the division does not receive corrected information within thirty (30) calendar days, it will be assumed to be correct, unless the pharmacy files a protest in accordance with subsection (2)(D) of this regulation.

(2) Payment of the PRA.

(A) Offset.

1. Each pharmacy may request that its PRA offset against any MO HealthNet payment due to that pharmacy.

A statement authorizing the offset must be on file with the division before any offset may be made relative to the PRA by the pharmacy.

B. Assessments shall be allocated and deducted over the applicable service period.

C. Any balance due after the offset shall be remitted to the director of the Department of Revenue and be deposited in the state treasury to the credit of the Pharmacy Reimbursement Allowance Fund.

D. If the remittance is not received before the next MO HealthNet payment cycle, the division shall offset the balance due from that check.

(B) Check.

1. If no offset has been authorized by the pharmacy, the division will begin collecting the pharmacy reimbursement allowance on the first day of each month for the preceding month.

2. The PRA shall be remitted by the pharmacy to the department. The remittance shall be made payable to the director of the Department of Revenue and be deposited in the state treasury to the credit of the Pharmacy Reimbursement Allowance Fund.

(C) Failure to comply with this request for information or failure to pay the PRA.

1. If a pharmacy fails to comply with a request for information from the MO HealthNet Division or fails to pay its PRA within thirty (30) days of notice, the PRA shall be delinquent.

2. For any delinquent PRA, the department may:

A. Proceed to enforce the state’s lien on the property of the pharmacy;

B. Cancel or refuse to issue, extend, or reinstate the MO HealthNet provider agreement; or

C. Seek denial, suspension, or revocation of license granted under Chapter 338, RSMo.

3. The new owner, as a result of a change in ownership, shall have his/her PRA paid by the same method the previous owner elected.

(D) Each pharmacy, upon receiving written notice of the final determination of its PRA, may file a protest with the director of the department setting forth the grounds on which the protest is based. Within thirty (30) days from the date of receipt of written notice from the department, the director of the department shall reconsider the determination and, if the pharmacy so requested, grant the pharmacy a hearing to be held within forty-five (45) days after the protest was filed, unless extended by agreement between the pharmacy and the director. The director shall issue a final decision within forty-five (45) days of the completion of the hearing. After a final decision by the director, a pharmacy's appeal of the director's final decision shall be to the Administrative Hearing Commission in accordance with section 208.156, RSMo 2000 and section 621.055, RSMo Supp. 2008.

(E) PRA Rates.

1. The PRA tax rate will be a uniform effective rate of one and twenty hundredths percent (.20%) with an aggregate annual adjustment, by the MO HealthNet Division, not to exceed five hundredths percent (.05%) based on the pharmacy's total prescription volume.

2. Beginning January 1, 2010, the PRA tax rate will be a uniform effective rate of one and eighty-two hundredths percent (1.82%) with an aggregate quarterly adjustment, by the MO HealthNet Division, not to exceed five tenths percent (0.5%) based on the pharmacy's total prescription volume.

3. The maximum rate shall be five percent (5%).


13 CSR 70-20.330 Medication Therapy Management (MTM) Program

PURPOSE: This rule establishes the regulatory basis for the administration of the MO HealthNet Medication Therapy Management (MTM) program, including designation of professional persons who may perform medication therapy management services and defined covered services within the program.

PUBLISHER’S NOTE: The secretary of state has determined that the publication of the entire text of the material which is incorporated by reference as a portion of this rule would be unduly onerous or expensive.
Chapter 20—Pharmacy Program

This material as incorporated by reference in this rule shall be maintained by the agency at its headquarters and shall be made available to the public for inspection and copying at no more than the actual cost of reproduction. This note applies only to the reference material. The entire text of the rule is printed here.

(1) Administration. The Medication Therapy Management (MTM) program shall be administered by the Department of Social Services, MO HealthNet Division. The MTM services covered, the program limitations, and the maximum allowable fees for all covered services shall be determined by the Department of Social Services, MO HealthNet Division, and shall be included in the pharmacy provider manual and provider bulletins, which are incorporated by reference and made a part of this rule, as published by the Department of Social Services, MO HealthNet Division, 615 Howerton Court, Jefferson City, MO 65109, at its website at dss.mo.gov/mhd/index.htm, September 1, 2015. This rule does not incorporate any subsequent amendments or additions.

(2) Persons Eligible. A person who is eligible for Title XIX (Medicaid) or Title XXI (State Children’s Health Insurance Program) or Blind Pension and who meets certain disease-based criteria included in their health profile.

(3) Provider Participation. To be eligible for participation in the MO HealthNet MTM program, a provider must be a qualified Missouri licensed pharmacist and have an active MO HealthNet provider status, and must have successfully completed two (2) hours of ACPE (Accreditation Council for Pharmacy Education) accredited continuing education focused on the administration of MTM approved by the MO HealthNet Division.

(4) Medication Therapy Management Services. MTM Services are available to any currently eligible non-managed care MO HealthNet participant for whom the qualifying pharmacist receives a MO HealthNet directed electronic drug utilization review (DUR) message through a Point-of-Sale transaction. MO HealthNet uses a clinically based rules engine that juries which participants require MTM interventions based on nationally accepted evidence-based guidelines. Pharmacists are then messaged about only those participants who are identified for one (1) or more issues pertinent to the evidence-based criteria. The rules engine uses current nationally accepted evidence-based guidelines for clinically appropri-
be dropped from the medical or outpatient claim. If an NDC is not provided, the J-Code will remain on the claim to report the denied line. If the drug being provided does not have a J-Code associated with it, the appropriate Healthcare Common Procedure Coding System (HCPCS) procedure code should be submitted with an NDC. For drugs without a valid HCPCS procedure code, revenue code 0250 “General Classification: Pharmacy” must be used with the appropriate NDC. Only drugs and items used during outpatient care in the hospital are covered. Take-home medications and supplies are not covered by MHD under the Hospital Program.

(4) A critical component to submitting claims with an NDC is to ensure that the appropriate HCPCS procedure code is billed with each NDC. To ensure accurate billing of drug charges, MHD will use the Noridian Crosswalk (www.dmedpdc.com) to determine whether the appropriate HCPCS procedure code is billed for the submitted NDC. Claims will be denied if the NDC submitted is not valid for the HCPCS procedure code submitted.

(5) Effective for dates of service on or after April 1, 2016, MO HealthNet Division (MHD) will require the National Drug Code (NDC) for all medications administered in the clinic or outpatient hospital setting, to comply with federal law. MHD must collect the eleven- (11-) digit NDC on all outpatient drug claims submitted to MHD from all providers for rebate purposes in order to receive federal financial participation. Providers will be required to submit their claims with the exact NDC that appears on the product dispensed or administered to receive payment from MHD. The NDC is found on the medication’s packaging and must be submitted in the five (5) digit – four (4) digit – two (2) digit format. If the NDC does not appear in the five (5) digit – four (4) digit – two (2) digit format on the packaging, zero(s) (0) may be entered in front of the section that does not have the required number of digits.

(6) All drug claims shall be routed through an automated computer system to apply edits specifically designed to ensure effective drug utilization. The Preferred Drug List (PDL) and clinical edits are designed to enhance patient care and optimize the use of program funds through therapeutically prudent use of pharmaceuticals. The edits are based on evidence-based clinical criteria and nationally recognized peer-reviewed information. This clinical information is paired with fiscal evaluation and then developed into a therapeutic class PDL recommendation. The PDL process incorporates clinical edits, including step therapies, into the MHD pharmacy program. Claims for drugs will automatically and transparently be approved for those patients who meet any of the system approval criteria. For those patients who do not meet the system approval criteria, the drugs will require a call to the MHD Drug Prior Authorization hotline at (800) 392-8030 to initiate a review and potentially authorize payment of claims. Providers may also use the CyberAccess tool to prospectively determine if a drug is a preferred agent or requires edit override, electronically initiate an edit override review, and to review a participant’s MHD paid claim history.

(7) The quantity to be billed for injectables and other types of medications dispensed to MHD participants must be calculated as follows:

(A) Containers of medication in solution (for example, ampoules, bags, bottles, vials, syringes) must be billed by exact cubic centimeters or milliliters (cc or mL) dispensed, even if the quantity includes a decimal (e.g., if three (3) 0.5 mL vials are dispensed, the correct quantity to bill is 1.5 mL);

(B) Single dose syringes and single dose vials must be billed per cubic centimeters or milliliters (cc or mL), rather than per syringe or per vial;

(C) Ointments must be billed per number of grams even if the quantity includes a decimal;

(D) Eye drops must be billed per number of cubic centimeters or milliliters (cc or mL) in each bottle even if the quantity includes a decimal;

(E) Powder filled vials and syringes that require reconstitution must be billed by the number of vials;

(F) Combination products, which consist of devices and drugs, designed to be used together, are to be billed as a kit. Quantity will be the number of kits used;

(G) The product Herceptin, by Genentech, must be billed by milligram rather than by vial due to the stability of the drug; and

(H) Non-Vaccines for Children (VFC) Immunizations and vaccines must be billed by the cubic centimeters or milliliters (cc or mL) dispensed, rather than per dose.

(8) Contrast materials and radiopharmaceuticals used in radiologic procedures may be billed separately using the appropriate HCPCS code and/or the NDC representing the materials or agent used in the procedure. If available, MHD would prefer the NDC for reporting purposes. If the material or agent used does not have an NDC, the appropriate HCPCS code alone is acceptable. All HCPCS codes for contrast materials and radiopharmaceuticals are manually priced and must be billed with the manufacturer’s invoice of cost attached to the claim.
